Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward

Triple negative breast cancer (TNBC) is a very aggressive subtype of breast cancer that lacks estrogen, progesterone, and HER2 receptor expression. TNBC is thought to be produced by Wnt, Notch, TGF-beta, and VEGF pathway activation, which leads to cell invasion and metastasis. To address this, the use of phytochemicals as a therapeutic option for TNBC has been researched. Plants contain natural compounds known as phytochemicals. Curcumin, resveratrol, and EGCG are phytochemicals that have been found to inhibit the pathways that cause TNBC, but their limited bioavailability and lack of clinical evidence for their use as single therapies pose challenges to the use of these phytochemical therapies. More research is required to better understand the role of phytochemicals in TNBC therapy, or to advance the development of more effective delivery mechanisms for these phytochemicals to the site where they are required. This review will discuss the promise shown by phytochemicals as a treatment option for TNBC.

Automated summary

Triple negative breast cancer (TNBC) is an aggressive subtype that lacks certain receptors. Phytochemicals, such as curcumin, resveratrol, and EGCG, show promise in inhibiting TNBC pathways. However, their limited bioavailability and lack of clinical evidence pose challenges for their use as single therapies. More research is needed to understand the role of phytochemicals in TNBC therapy and develop effective delivery mechanisms. This review discusses the potential of phytochemicals as a treatment option for TNBC.